Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC)

Glenmark Therapeutics Inc., USA launches Pump Packs for Adapalene Gel USP, 0.1% (OTC) Elmwood Park, New Jersey, October 06, 2026 – Glenmark Therapeutics Inc., USA (Glenmark) is pleased to announce the launch1 of Adapalene Gel USP, 0.1% (OTC) in new pump packs . Glenmark’s Adapalene Gel USP, 0.1% can be compared to the active ingredient of Differin®2 Gel, 0.1%. According to Nielsen® syndicated data for the latest 52-week period ending September 5, 2026, the Differin® Gel, 0.1% (OTC) market3 achieved annual sales of approximately $45.8 million*. Commenting on the launch, Marc Kikuchi, President & Business Head, North America, said, “The introduction of Adapalene Gel USP, 0.1% (OTC) in a new pump pack enhances consumer experience by offering a convenient and easy to use dispensing option while further strengthening our growing U.S. dermatology portfolio . This launch reflects our commitment to delivering high- quality and affordable healthcare solutions that meet evolving consumer needs.” For product information and how to purchase, please visit: Adapalene Gel USP, 0.1% - 15 g Pump on Amazon Adapalene Gel USP, 0.1% - 45 g Pump on Amazon Adapalene Gel USP, 0.1% - 15 g Pump on Walmart.com Adapalene Gel USP, 0.1% - 45 g Pump on Walmart.com 1Glenmark’s Adapalene Gel USP, 0.1% (OTC) is only marketed for the indications listed in Glenmark’s approved drug facts label. 2This product is not manufactured or distributed by Galderma Laboratories, L.P. and/or Galderma Holding S.A., distributor of DIFFERIN® Gel and owner of the registered trademark DIFFERIN®, respectively. [Galderma does not make or license Glenmark’s product.] 3Market includes brand and all available therapeutic equivalents. Note: IQVIA® data obtained by Glenmark is only available for all approved RLD indications. Glenmark’s product is only approved for and will only be marketed for the indications listed in Glenmark’s approved label, which may be different than the approved RLD indications. *Nielsen® NIQ Discover; Syndicated Data for Period Ending September 5, 2026 About Glenmark Pharmaceuticals Limited Glenmark Pharmaceuticals Ltd. (BSE: 532296 | NSE: GLENMARK) is a global, research‐led pharmaceutical company with a unique focus on innovation and accessibility. We pioneer transformative breakthrough therapies that aim to redefine treatment while expanding access to high quality and affordable medicines for patients around the world. With 11 world-class manufacturing facilities across four continents, supported by six cutting-edge R&D centres, and a commercial footprint in 80+ countries, we deliver a diversified portfolio across branded, innovative, generics, and consumer health products, with a focus on respiratory, dermatology, and oncology. Scrip 100 positions Glenmark among the Top 100 biopharmaceutical companies globally by pharmaceutical sales for 2024. For more information, visit www.glenmarkpharma.com. For more information, please contact: India United States Akhila Natarajan [email protected] +91 22 4018 9999 Adfactors PR [email protected] +91 9535635461 Akhila Natarajan [email protected] Danielle Hagen [email protected] 202-365-6112

The release as fetched from its publisher. glenmarkpharma.com ↗